NAMS
NewAmsterdam Pharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
NAMS fundamentals
NewAmsterdam Pharma (NAMS) expects to report earnings on Aug 6, 2025, with estimated revenue of 1.81M (YoY -20.58%), and EPS at -0.505594 (YoY -23.32%).
Revenue estimate / YoY
1.81M
-20.58%
EPS estimate / YoY
-0.505594
-23.32%
Report date
Aug 6, 2025
EPS
Revenue
Revenue & Expenses
NAMS has released its 2025 Q1 earnings report, with revenue of 2.98M, reflecting a YoY change of 112.56%, and net profit of -39.53M, showing a YoY change of 57.85%. The Sankey diagram below clearly presents NAMS's revenue sources and cost distribution.
Key Indicators
NewAmsterdam Pharma (NAMS) key financial stats and ratios, covering profitability, financial health, and leverage.
NewAmsterdam Pharma (NAMS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
NewAmsterdam Pharma (NAMS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
NewAmsterdam Pharma (NAMS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does NewAmsterdam Pharma (NAMS) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track NewAmsterdam Pharma (NAMS) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
Did NewAmsterdam Pharma beat or miss consensus estimates last quarter?What were the key takeaways from NewAmsterdam Pharma’s earnings call?How were NewAmsterdam Pharma’s latest financial results overall?What is NewAmsterdam Pharma’s gross profit margin?What is the market’s earnings forecast for NewAmsterdam Pharma next quarter?What guidance did NewAmsterdam Pharma’s management provide for the next earnings period? What factors drove the changes in NewAmsterdam Pharma’s revenue and profit?What is the revenue and EPS growth rate for NewAmsterdam Pharma year over year?